MeCP2 regulates Gdf11, a dosage-sensitive gene critical for neurological function

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Mutations in the methyl-CpG binding protein 2 (MeCP2) gene cause Rett syndrome (RTT) and MECP2 duplication syndrome (MDS).
• Identifying genes precisely controlled by MeCP2 is crucial for understanding these neurological disorders.
• MeCP2's role in gene regulation is complex and requires further elucidation.

Purpose of the Study:

• To identify genes regulated by MeCP2.
• To investigate the role of growth differentiation factor 11 (Gdf11) in MeCP2-related disorders.
• To assess the therapeutic potential of normalizing Gdf11 levels.

Main Methods:

• Integrated multiple transcriptomics datasets to identify MeCP2-regulated genes.
• Analyzed Gdf11 expression in mouse models of RTT and MDS.
• Utilized genetic manipulation to normalize Gdf11 dosage in MDS mouse models.
• Assessed neurobehavioral deficits and survival in mice with altered Gdf11 levels.

Main Results:

• MeCP2 was found to finely regulate Gdf11 expression.
• Gdf11 levels were decreased in RTT models and increased in MDS models.
• Restoring normal Gdf11 levels ameliorated behavioral deficits in MDS mice.
• Loss of one Gdf11 copy induced hyperactivity and impaired learning/memory in mice.
• Reduced Gdf11 levels decreased survival rates in mice.

Conclusions:

• Gdf11 is a key downstream target of MeCP2.
• Gdf11 dosage is critical for normal brain function and behavior.
• Modulating Gdf11 levels presents a potential therapeutic strategy for MeCP2-related disorders.